SCHEDULE: Polar Capital Amends Arcutis Biotherapeutics Stake

Polar Capital Holdings Plc and its affiliates have updated their beneficial ownership in Arcutis Biotherapeutics, Inc., reporting a 4.2% stake as of June 30, 2025.

Summary

• Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC Biotechnology Fund have filed an Amendment No. 3 to their Schedule 13G.
• The filing reports their beneficial ownership in Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) Common Stock.
• As of June 30, 2025, the reporting persons collectively beneficially own 5,006,472 shares.
• This represents 4.2% of Arcutis Biotherapeutics' outstanding Common Stock.
• The percentage is based on 119,201,724 shares outstanding, as reported in Arcutis Biotherapeutics' Form 10-Q on May 6, 2025.
• The shares are held with sole voting and sole dispositive power by the reporting entities.
• The acquisition and holding of these securities are certified to be in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine ownership disclosure, indicating continued institutional interest in Arcutis Biotherapeutics, albeit at a stake below the 5% threshold. No negative intent or significant divestment is indicated.

Positives

• Polar Capital, a significant institutional investor, maintains a substantial stake in Arcutis Biotherapeutics, indicating continued investment interest.
• The filing confirms that the investment is for ordinary course of business purposes, not for control, which suggests a passive, long-term investment perspective.

Negatives

• The reported beneficial ownership of 4.2% is below the 5% threshold, which might indicate a slight reduction in stake or a rebalancing of portfolio, though the exact change from previous filings is not detailed here.

Risks

• The value of the investment is subject to market fluctuations inherent in common stock holdings.
• The investment is concentrated in a single issuer, Arcutis Biotherapeutics, Inc., exposing the holder to company-specific risks.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or the reporting person's future investment intentions beyond the certification that shares are held in the ordinary course of business.

Industry Context

This Schedule 13G filing is a routine disclosure by an institutional investor, Polar Capital, regarding its passive stake in Arcutis Biotherapeutics, a company in the biotechnology sector. Such filings provide transparency into significant ownership positions, which can be of interest to other investors tracking institutional sentiment and major shareholder activity within the highly dynamic biotechnology industry.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional investor's stake, which can influence market perception and liquidity.
• Management: Awareness of a large, passive institutional holder, though without direct control implications.

Key Dates

Keywords

Arcutis Biotherapeutics, Polar Capital, Biotechnology, Pharmaceuticals, Investment, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor